Related Experiment Video
Updated: Dec 23, 2025
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.1K
Report from the 5th cardiovascular outcome trial (CVOT) summit
Oliver Schnell1, Eberhard Standl2, Xavier Cos3
1Forschergruppe Diabetese e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de.
Cardiovascular Diabetology
|April 19, 2020
Summary
The 5th Cardiovascular Outcome Trial Summit discussed recent trials like CAROLINA and CREDENCE, focusing on diabetes and heart failure treatment updates. Key insights impact new algorithms for managing cardiovascular and kidney disease in diabetic patients.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- The 5th Cardiovascular Outcome Trial (CVOT) Summit convened in Munich, Germany, on October 24th-25th, 2019.
- This annual meeting serves as a critical forum for discussing recently completed and presented CVOTs.
Framework:
- This year's summit specifically focused on pivotal trials: CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6.
- Discussions emphasized the implications of these trials for diabetes management and the development of new treatment algorithms.
Implementation:
- The summit highlighted the role of SGLT-2 inhibitors and GLP-1 receptor agonists in managing heart failure and diabetic kidney disease.
- Discussions extended to the impact of CVOTs on primary prevention strategies and primary care.
Implications:
- Findings from these CVOTs are crucial for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners.
- The summit advanced understanding of therapeutic options, including Angiotensin Receptor-Neprilysin Inhibitors (ARNI), for heart failure and kidney disease in diverse patient populations.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
530
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
530
01:27Coronary Artery Disease V: Interprofessional Care
179
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
179
01:30Acute Coronary Syndrome III: Diagnostic Studies
145
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
145
01:28Acute Coronary Syndrome IV: Interprofessional Care
166
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
166
01:23Assessment of the Cardiovascular System I: Subjective Data
690
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
690
01:30Acute Coronary Syndrome I: Introduction
578
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
578